Summary of the II International Consensus Symposium on Combined Antiviral Therapy and Implications for future therapies

Antiviral Research

Volumn 35, Issue 2, 1997, Pages 65-82

  De Jong, Menno D ^a   Boucher, Charles A B ^b   Cooper, David A ^c   Galasso, George J ^d   Gazzard, Brian ^e   Lange, Joep M A ^f   Montaner, Julio S ^g   Richman, Douglas D ^h   Thomas, Howard C ⁱ  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d Natl Found for Biomed Research   (United States)

^e CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^f UNIVERSITY OF AMSTERDAM   (Netherlands)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMANTADINE; ANTIVIRUS AGENT; CIDOFOVIR; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON; LAMIVUDINE; MONOCLONAL ANTIBODY; PENCICLOVIR; POLYCLONAL ANTIBODY; RIBAVIRIN; RIMANTADINE; VALACICLOVIR; ZANAMIVIR;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; CYTOMEGALOVIRUS; DRUG METABOLISM; EPSTEIN BARR VIRUS; FILOVIRIDAE; HANTAVIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HERPES SIMPLEX VIRUS; HERPES VIRUS; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; INFLUENZA VIRUS; NONHUMAN; PARAINFLUENZA VIRUS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RHINOVIRUS; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; VIRUS REPLICATION; WART VIRUS;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FORECASTING; HUMANS;

CYTOMEGALOVIRUS; DELTA VIRUS; FILOVIRIDAE; HANTAVIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HERPES; HERPESVIRIDAE; HERPESVIRUS 8; HUMAN HERPESVIRUS 3; HUMAN HERPESVIRUS 4; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN PAPILLOMAVIRUS TYPES; INFLUENZA VIRUS; RESPIRATORY SYNCYTIAL VIRUS; RHINOVIRUS; SIMPLEXVIRUS;

EID: 0030965718     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(97)00020-X     Document Type: Conference Paper

References (129)

1. Ambroziak, J.A., Blackbourn, D.J., Herndier, B.G., Glugau, R.G., Gullett, J.H., McDonald, A.R., Lennette, E.T., Levy, J.A., 1995. Herpesvirus-like sequences in HIV-infected and uninfected Kaposi's sarcoma patients. Science 268, 582-583.
2. Anon., 1993. Update: Hantavirus Disease-United States, MMWR 42, pp. 612-614.
3. Aschan, J., Ringden, O., Ljungman, P., Lonnqvist, B., Ohlman, S., 1992. Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients. Scand. J. Infect. Dis. 24, 143-150.
4. Bacon, T.H., Boyd, M.R., 1995. Actvity of penciclovir against Epstein-Barr virus. Antimicrob. Agents Chemother. 39, 1599-1602.
5. Baldantini, F., Underwood, M.R., Stanat, S.C., et al., 1996. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer gaciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J. Virol. 170, 1390-1395.
6. Bartholomew, M.M., Jansen, R.W., Jeffers, L.J., et al., 1997. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349, 20-22.
7. Benhamou, Y., Dohin, E., Lunel-Fabiani, F., Poynard, T., Huraux, J.M., Katlama, C., Opolon, P., Gentilini, M., 1995. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 345, 396-397.
8. Beutner, K.R., Friedman, D.J., Forszpaniak, C., Andersen, P.L., Wood, M.J., 1995. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob. Agents Chemother. 39, 1546-1553.
9. Bigoni, B., Dolcetti, R., De Lellis, L., Carbone, A., Boiocchi, M., Cassai, E., Di Luca, D., 1996. Human herpesvirus 8 is present in the lymphoid system of healthy persons and can reactivate in the course of AIDS. J. Infect. Dis. 173, 542-549.
10. Biron, F., Lucht, F., Peyramond, D., Fresard, A., Vollet, T., Nugier, F., Grange, J., Malley, S., Hamedi-Sangsoni, F., Vila, J., 1995. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J. AIDS Hum. Retrovirol. 10, 36-40.
11. Boivin, G., Chou, S., Quirk, M.R., Erice, A., Jordan, M.C., 1996. Detection of ganciclovir resistance mutations and quantitation of cytomegalovirus (CMV) DNA in leucocytes of patients with fatal disseminated CMV disease. J. Infect. Dis. 173, 523-528.
12. Bosch, O., Moraleda, G., Castillo, I., Careno, V., 1993. Treatment of chronic hepatitis B with recombinant interferon alpha versus recombinant interferon alpha plus levamisole. J. Hepatol. 19, 437-441.
13. Boshoff, C., Schulz, T.F., Kennedy, M.M., 1995a. Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nature Medicine 1, 1274-1278.
14. Boshoff, C., Whitby, D., Hatziioannou, T., Fisher, C., van der Walt, J., Hatzakis, A., Weiss, R., Schulz, T., 1995b. Kaposi's sarcoma-associated herpesvirus in HIV-negative Kaposi's sarcoma. Lancet 345, 1043-1044.
15. Braconier, J.H., Paulsen, O., Engman, K., Widell, A., 1995. Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: a pilot study. Scand. J. Infect. Dis. 27, 325-329.
16. Brillanti, S., Garson, J., Foli, M., Whitby, K., Denville, R., Masci, C., Miglioli, M., Barbara, L., 1994. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 107, 812-817.
17. Brillanti, S., Miglioli, M., Barbara, I., 1995. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. J. Hepatol. 23 (Suppl. 2), 13-15.
18. Brook, M.G., Karayiannis, P., Thomas, H.C., 1989. Which patients with chronic hepatitis B virus infection will respond to alfa-interferon therapy? A statistical analysis of predictive factors. Hepatology 10, 761-763.
19. Bruhn, F.W., Yeager, A.S., 1977. Respiratory syncytial virus in early infancy: circulating antibody and the severity of infection. Am. J. Dis. Child. 131, 145-148.
20. Cesarman, E., Chang, Y., Moore, P.S., Said, J.W., Knowles, D.M., 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med. 332, 1186-1191.
21. Chang, Y., Cesarman, E., Pessin, M.S., Lei, F., Culpepper, J., Knowles, D.M., Moore, P.S., 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266, 1865-1869.
22. Chemello, L., Cavaletto, L., Bernardinello, E., Guido, M., Pontisso, P., Alberti, A., 1995. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J. Hepatol. 23 (Suppl. 2), 8-12.
23. Cobian, L., Houston, S., Greene, J., Sinnot, J.T., 1995. Parainfluenza virus respiratory infection after heart transplantation: successful treatment with ribavirin. Clin. Infect. Dis. 21, 1040-1041.
24. Coffin, J.M., 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267, 483-489.
25. Cohard, M., Poynard, T., Mathurin, P., Zarski, J.P., 1994. Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect metanalysis. Hepatology 20, 1390-1398.
26. Crump, C.E., Arruda, E., Hayden, F.G., 1994. Comparative antirhinoviral activities of soluble intercellular adhesion molecule-1 (sICAM-1) and chimeric ICAM-1/immunoglobulin A molecule. Antimicrob. Agents Chemother. 38, 1425-1427.
27. Davis, C.L., Harrison, K.L., McVicar, J.P., Forg, P.J., Bronner, M.P., Marsh, C.L., 1995. Antiviral prophylaxis and the Epstein-Barr virus-related post-transplant lymphoproliferative disorder. Clin. Transplant. 9, 53-59.
28. De Jong, M.D., Boucher, C.A.B., Galasso, G.J., Hirsch, M.S., Kern, E.R., Lange, J.M.A., Richman, D.D., 1996. Consensus symposium on combined antiviral therapy. Antiviral Res. 29, 5-29.
29. De Lellis, L., Fabris, M., Cassai, E., Corallini, A., Giraldo, G., Feo, C., Monini, P., 1995. Herpesvirus-like DNA sequences in non-AIDS Kaposi's sarcoma. J. Infect. Dis. 172, 1605-1607.
30. Decker, L.L., Shankar, P., Khan, G., Freeman, R.B., Dezube, B.J., Lieberman, J., Thorley-Lawson, D.A., 1996. The Kaposi sarcoma-associated herpesvirus (KSHV) is present as an intact latent genome in KS tissue but replicates in the peripheral blood mononuclear cells of KS patients. J. Exp. Med. 184, 283-288.
31. Dienstag, J.L., Perrillo, R.P., Schiff, E.R., Bartholomew, M., Vicary, C., Rubin, M., 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333, 1657-1661.
32. Emanuel, D., Cunningham, I., Jules-Elysee, K., Brochstein, J.A., Kernan, N.A., Laver, J., Stover, D., White, D.A., Fels, A., Polsky, B., Castro-Malaspina, H., Peppard, J.R., Bantis, P., Hammarling, V., O'Reilly, R.J., 1988. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann. Intern. Med. 109, 777-782.
33. Englund, J.A., Sullivan, C.J., Jordan, C.M., Deliner, L.P., Vercellotti, G.M., Balfour Jr., H.H., 1988. Respiratory syncytial virus infection in immunocompromised adults. Ann. Intern. Med. 109, 203-208.
34. Enting, R., De Gans, J., Reiss, P., Jansen, C., Portegies, P., 1992. Ganciclovir/foscarnet for cytomegalovirus meningoencephalitis in AIDS. Lancet 340, 559-560.
35. Epstein, J.B., Ransier, A., Sherlock, C.H., Spinelli, J.J., Reece, D., 1996. Acyclovir prophylaxis of oral herpes virus during bone marrow transplantation. Eur. J. Cancer 32B, 158-162.
36. Farci, P., Mandas, A., Coiana, A., Lai, M.E., Desmet, V., van Eyleen, P., Gibo, Y., Caruso, L., Scaccabarozzi, S., Criscuolo, D., Ryff, J.C., Balestrieri, A., 1994. Treatment of chronic hepatitis D with interferon alfa-2a. N. Engl. J. Med. 330, 88-94.
37. Fattovich, G., Giustina, G., Brollo, L., Guido, M., Pontisso, P., Noventa, F., Alberti, A., 1992. Therapy for chronic hepatitis B with lymphoblastoid interferon-alpha and levamisole. Hepatology 16, 1115-1119.
38. Fulginiti, V.A., Eller, J.J., Sieber, O.F., Joyner, J.W., Minamitani, M., Meiklejohn, G., 1969. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines: an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. 89, 435-448.
39. Gao, S.J., Kingsley, L., Li, M., Cheng, W., Parravicini, C., Ziegler, J., Newton, R., Rinaldo, C.R., Saah, A., Phair, J., Detels, R., Chang, Y., Moore, P.S., 1996. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nature Med 2, 925-928.
40. Gelfand, E., 1983. Ribavirin treatment of viral pneumonia in severe combined immunodeficiency. Lancet 1, 732-733.
41. Gilbert, B.E., Wyde, P.R., Ambrose, M.W., Wilson, S.Z., Knight, V., 1992. Further studies with short duration ribavirin aerosol for the treatment of influenza virus infection in mice and respiratory syncytial virus infection in cotton rats. Antiviral Res. 17, 33-42.
42. Glesby, M.J., Hoover, D.R., Weng, S., Graham, N.M., Phair, J.P., Datels, R., Hu, M., Saah, A.J., 1996. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the multicenter AIDS cohort study. J. Infect. Dis. 173, 1477-1480.
43. Glezen, W.P., Parades, A., Allison, J.A., et al., 1981. Risk of respiratory syncytial virus infection for infants from low income families in relationship to age, sex, ethnic group and maternal antibody level. J. Pediatr. 98, 708-715.
44. Harrington, R.D., Hooton, R.D., Hackman, R.C., et al., 1992. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J. Infect. Dis. 165, 987-993.
45. Hayden, F.G., 1986. Combinations of antiviral agents for treatment of influenzavirus infections. J. Antimicrob. Chemother. 18 (Suppl. B), 77-83.
46. Hayden, F.G., Hay, A.J., 1992. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr. Top. Microbiol. Immunol. 176, 119-130.
47. Hayden, F.G., Treanor, J.J., Betts, R.F., Lobo, M., Esinhart, J.D., Hussey, E.K., 1996. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 275, 295-299.
48. Heijtink, R.A., De Wilde, G.A., Kruining, J., et al., 1993. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res. 21, 141-153.
49. Hemming, V.G., Prince, G.A., Groothuis, J.R., Siber, G.R., 1995. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin. Microbiol. Rev. 8, 22-33.
50. Hemming, V.G., Rodriguez, W., Kim, H.W., et al., 1987. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children. Antimicrob. Agents Chemother. 31, 1882-1886.
51. Hertz, M.I., Englund, J.A., Snover, D., et al., 1989. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature. Medicine 68, 269-281.
52. Ho, D.D., Neumann, A.U., Perelson, A.S., Chen, W., Leonard, J.M., Markowitz, M., 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126.
53. Hosoya, M., Shigeta, S., Ishii, T., Suzuki, H., De Clercq, E., 1993. Comparative inhibitory effects of various nucleoside nd nonucleoside analogues on replication of influenza virus types A and B in vitro and in ovo. J. Infect. Dis. 168, 641-646.
54. Huang, Y.Q., Li, J.J., Kapian, M.H., Poiesz, B., Katabira, E., Zhang, W.L., Feiner, D., Friedman-Kien, A.E., 1995. Human herpesvirus-like nucleic acid in various forms of Kaposi's sarcoma. Lancet 345, 759-761.
55. Huggins, J.W., Hsiang, C.M., Cosgriff, T.M., Guang, M., Smith, J.I., Wu, Z.O., le Duc, J.W., Zheng, Z.M., Meegan, J.M., Wong, G.N., Oland, D.D., Gui, X.E., Gibbs, P.H., Yuan, G.H., Zhang, T.M., 1991. Prospective double-blind concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J. Infect. Dis. 164, 1119-1127.
56. Humphrey, R.W., O'Brien, T.R., Newcomb, F.M., Nishihara, H., Wyvill, K.M., Ramos, G.A., Saville, M.W., Goedert, J.J., Strauss, S.E., Yarchoan, R., 1996. Kaposi's sarcoma (KS)-associated herpes virus-like DNA sequences in peripheral blood mononuclear cells: association with KS and persistence in patients receiving anti-herpes drugs. Blood 88, 297-301.
57. Jacobson, M.A., Kramer, F., Bassiakos, Y., Hooton, T., Polsky, B., Geheb, H., O'Donnell, J.J., Walker, J.O., Korvick, J.A., van der Horst, C., 1994. Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS Clinical Trials Group Protocol 151. J. Infect. Dis. 170, 189-193.
58. Kapikian, A.Z., Mitchell, R.H., Chanock, R.M., Shvedoff, R.A., Stewart, C.E., 1969. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus ifection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89, 405-421.
59. Katzenstein, D.A., Hammer, S.M., Hughes, M.D., Gundacker, H., Jackson, J.B., Fiscus, S., Rasheed, S., Elbeik, T., Reichman, R., Japour, A., Merigan, T.C., Hirsch, M.S., 1996. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N. Engl. J. Med. 335, 1091-1098.
60. Kedes, D.E., Operskalski, E., Busch, M., Kohn, R., Flood, J., Ganem, D., 1996. The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nature Medicine 2, 918-924.
61. Kelloff, G.J., Boone, C.W., Crowell, J.A., 1995. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary. J. Cell. Biochem. (Suppl. 23), 1-9.
62. Kim, H.W., Canchola, J.G., Brandt, C.D., et al., 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89, 422-434.
63. Knox, K.K., Drobyski, W.R., Carrigan, D.R., 1991. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from marrow transplant patient. Lancet 2, 1292-1293.
64. Korba, E., 1996. In vitro evaluation of combination strategies against heptitis B virus replication. Antiviral Res. 29, 49-51.
65. Kovacs, J.A., Baseler, M., Dewar, M.J., Vogel, S., Davey, R.J., Falloon, J., Polis, M.A., Walker, R.E., Stevens, R., Salzman, N.P., Metcalf, J.A., Masur, H., Lane, H.C., 1995. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N. Engl. J. Med. 332, 567-575.
66. Kovacs, J.A., Vogel, S., Albert, J.M., Falloon, J., Davey, R.T., Wallace, R.E., Polis, M.A., Spooner, K., Metcalf, J.H., Baseler, M., Fyfe, G., Lane, H.C., 1996. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 335, 1350-1356.
67. Lefrere, J.J., Meyohas, M.C., Mariotti, M., Meynard, J.L., Thauvin, M., Frottier, J., 1996. Detection of human herpesvirus 8 DNA sequences before the appearance of Kaposi's sarcoma in human immunodeficiency virus (HIV)-positive subjects with a known date of HIV seroconversion. J. Infect. Dis. 174, 283-287.
68. Lennette, E.T., Blackbourn, D.J., Levy, J.A., 1996. Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet 348, 858-861.
69. Levin, M.J., 1994. Treatment and prevention options for respiratory syncytial virus infections. J. Pediatr. 124, S22-S27.
70. Li, J.J., Huang, Y.Q., Cockerell, C.J., Friedman-Kien, A.E., 1996. Localization of human herpes-like virus type 8 in vascular endothelial cells and perivascular spindle-shaped cells of Kaposi's sarcoma lesions by in situ hybridization. Am. J. Pathol. 148, 1741-1748.
71. Ling, R., Mutimer, D., Ahmed, M., Boxall, E.H., Elias, E., Dusheiko, G.M., Harrison, I.J., 1996. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24, 711-713.
72. Luppi, M., Barozzi, P., Maiorana, A., Artusi, T., Trovato, R., Marasca, R., Savarino, M., Ceccherini-Nelli, L., Torelli, G., 1996a. Human herpesvirus-8 DNA sequences in human immunodeficiency virus-negative angioimmunoblastic lymphadenopathy and benign lymphadenopathy with giant germinal center hyperplasia and increased vascularity. Blood 87, 3903-3909.
73. Luppi, M., Barozzi, P., Marasca, R., Savarino, M., Torelli, G., 1996b. HHV-8-associated primary B-cell lymphoma in HIV-negative patient after long-term steroids. Lancet 347, 980.
74. Luxton, J.C., Williams, I., Weller, I., Crawford, D.H., 1993. Epstein-Barr virus infection of HIV-seropositive individuals is transiently suppressed by high-dose acyclovir treatment. AIDS 7, 1337-1343.
75. Martin, M.A., Bock, M.J., Phaller, M.A., Wenzel, R.P., 1988. Respiratory syncytial virus infections in adult bone marrow transplant recipients. Lancet 1, 1396-1397.
76. Martin, S., Casasnovas, J.M., Staunton, D.E., Springer, T.A., 1993. Efficient neutralization and disruption of rhinovirus by chimeric ICAM-1/immunoglobulin molecules. J. Virol. 67, 3561-3568.
77. Mellors, J.W., Kingsley, L.A., Rinaldo, C.R., Todd, J.A., Hoo, B.S., Kokka, R.P., Gupta, P., 1995. Quatitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann. Intern. Med. 122, 573-579.
78. Mellors, J.W., Rinaldo, C.R., Gupta, P., White, R.M., Todd, J.A., Kingsley, L.A., 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272, 1167-1170.
79. Milich, D.R., Wolf, S.F., Highes, J.L., Jones, J.E., 1995. Interleukin 12 suppresses autoantibody production by reversing helper T-cell phenotype in hepatitis Be antigen transgenic mice. Proc. Natl. Acad. Sci. USA 92, 6847-6851.
80. Monini, P., De Lellis, L., Fabris, M., Rigolin, F., Cassai, E., 1996. Kaposi's sarcoma-associated herpesvirus DNA sequences in prostate tissue and semen. N. Engl. J. Med. 334, 1168-1172.
81. Morfeldt, L., Torssander, J., 1994. Long term remission of Kaposi sarcoma following foscarnet treatment in HIV-infected patients. Scand. J. Infect. Dis. 26, 749-752.
82. Nador, R.G., Cesarman, E., Chadburn, A., Dawson, D.B., Ansani, M.C., Said, J., Knowles, D.M., 1996. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kapsosi's sarcoma-associated herpes virus. Blood 88, 645-656.
83. Noel, J.C., Hermans, P., Andre, J., Fayt, I., Simonart, Th., Verhest, A., Haot, J., Burny, A., 1996. Herpesvirus-like DNA sequences and Kaposi's sarcoma: relationship with epidemiology, clinical spectrum, and histologic features. Cancer 77, 2132-2136.
84. Nowak, M.A., Bonhoeffer, S., Hill, A.M., Boehme, R., Thomas, H.C., McDade, H., 1996. Viral dynamics in hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 93, 4398-4402.
85. O'Brien, W.A., Hartigan, P.M., Martin, D., Esinhart, J., Hill, A., Benoir, S., Rubin, M., Simberkoff, M.S., Hamilton, J.D., 1996. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N. Engl. J. Med. 334, 426-431.
86. O'Neill, E., Henson, T.H., Ghorbiani, A.J., Land, M.A., Webber, B.L., Garcia, J.V., 1996. Herpes virus-like sequeces are specifically found in Kaposi sarcoma lesions. J. Clin. Pathol. 49, 306-308.
87. Ohlin, A., Hoover-Litty, H., Sanderson, G., et al., 1994. Spectrum of activity of soluble intercellular adhesion molecule-1 against rhinovirus reference strains and field isolates. Antimicrob. Agents Chemother. 38, 1413-1415.
88. Otsuki, T., Kumar, S., Ensoli, B., Kingma, D.W., Yano, T., Stetler-Stevenson, M., Jaffe, E.S., Raffeld, M., 1996. Detection of HHV-8/KSHV DNA sequences in AIDS-associated extranodal lymphoid malignancies. Leukemia 10, 1358-1362.
89. Pari, G.S., Field, A.K., Smith, J.A., 1995. Potent antiviral activity of an antisense oligonucleotide complementary to the intron-exon boundary of human cytomegalovirus genes UL36 nd UL 37. Antimicrob. Agents Chemother. 39, 1157-1161.
90. Patterson, J.L., Fernandez-Larsson, R., 1990. Molecular mechanisms of action of ribavirin. Rev. Infect. Dis. 12, 1139-1145.
91. Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M., Ho, D.D., 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582-1586.
92. Peters, M., Timm, U., Schurmann, D., Pohle, H.D., Ruf, B., 1992. Combined and alternating ganciclovir and foscarnet in acute and maintenance therapy of human immunodeficiency virus-related cytomegalovirus encephalitis refractory to ganciclovir alone: A case report and review of the literature. Clin. Invest. 70, 456-458.
93. Pollard, R.B., 1996. CMV retinitis: ganciclovir/monoclonal antibody. Antiviral Res. 29, 73-75.
94. Pottage, J.C., Kessler, H.A., 1995. Herpes simplex virus resistance to acyclovir: clinical relevance. Inf. Agents Dis. 4, 115-124.
95. Prichard, M.N., Shipman, C.J., 1995. Ribonucleotide reductase: an important enzyme in the replication of herpes simplex virus type 1 and a target for antiviral chemotherapy. Chemotherapy 41, 384-395.
96. Reed, E.C., Bowden, R.A., Dandliker, P.S., Lilleby, K.E., Meyers, J.D., 1988. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann. Intern. Med. 109, 783-788.
97. Renne, R., Zhong, W., Herndier, B., McGrath, M., Abbey, N., Kedes, D., Ganem, D., 1996. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nature Medicine 2, 342-346.
98. Robert, C., Agbalika, F., Blanc, F., Dubertret, L., 1996. HIV-negative patient with HHV-8 DNA follicular B-cell lymphoma associated with Kaposi's sarcoma. Lancet 347, 1042-1043.
99. Rodriguez, W.J., Hall, C.B., Welliver, R., Simoes, E.A., Ryan, M.E., Stutman, H., Johnson, G., Van Dyke, R., Groothuis, J.R., Arrobio, J., 1994. Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial. J. Pediatr. 125, 129-135.
100. Rollins, B.S., Elkhatieb, A.H., Hayden, F.G., 1993. Comparative anti-influenza virus activity of 2′-deoxy-2′-fluororibosides in vitro. Antiviral Res. 21, 357-368.
101. Rosina, F., Cozzolongo, R., 1994. Interferon in HDV infection. Antiviral Res. 24, 165-174.
102. Ruiz-Moreno, M., Garcia, R., Rua, M.J., Serrano, B., Moraleda, G., Feijoo, E., Bartolome, J., Ortiz, F., Castillo, I., Carreno, V., 1993. Levamisole and interferon in children with chronic hepatitis B. Hepatology 18, 264-269.
103. Ryan, D.M., Ticehurst, J., Dempsey, M.H., 1995. GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob. Agents Chemother. 39, 2583-2584.
104. Ryan, D.M., Ticehurst, J., Dempsey, M.H., Penn, C.R., 1994. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob. Agents Chemother. 38, 2270-2275.
105. Safrin, S., Kemmerly, S., Plotkin, B., Smith, T., Weissbach, N., Deveranoz, P., Dhan, L.D., Cohn, P., 1994. Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J. Infect. Dis. 169, 193-196.
106. Said, W., Chien, K., Takeuchi, S., Tasaka, T., Asou, H., Cho, S.K., De Vos, S., Cesarman, E., Knowles, D.M., Kueffler, H.P., 1996. Kaposi's sarcoma-associated herpesvirus (KSHV or HHV-8) in primary effusion lymphoma: ultrastructural demonstration of herpesvirus in lymphoma cells. Blood 87, 4937-4943.
107. Sander, C.A., Simon, M., Puchta, U., Raffeld, M., Kind, P., 1996. HHV-8 in lymphoproliferative lesions in skin. Lancet 348, 475-476.
108. Sarasini, A.F., Baldantini, M., Furione, E., Percivalli, F., Brerra, R., Barbi, M., Gerna, G., 1995. Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients. J. Med. Virol. 47, 237-244.
109. Schalling, M., Ekman, M., Kaaya, E.E., Linde, A., Biberfeld, P., 1995. A role for a new herpes virus (KSHV) in different forms of Kaposi's sarcoma. Nature Medicine 1, 707-708.
110. Schooley, R.T., Ramirez-Ronda, C., Lange, J.M.A., Cooper, D.A., Laville, J., Lefkowitz, L., Moore, M., Laroer, B.A., St. Clair, M., Mulder, J.W., McKinnan, R., Pennington, U., Harrigan, D.R., Kinghorn, I., Steel, H., Rooney, J.F., 1996. Virologic and immunologic benefits of initial therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. J. Infect. Dis. 173, 1354-1366.
111. Schvarcz, R., Yun, Z.B., Sonnerborg, A., Weiland, O., 1995. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J. Med. Virol. 46, 43-47.
112. Shaw, T., Amor, P., Civitico, G., Boyd, M., Locarnini, S., 1994. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob. Agents Chemother. 38, 719-723.
113. Shepp, D.H., Dandliker, P.S., De Miranda, P., Burnette, T.C., Cederberg, D.M., Kirk, L.E., Myers, J.D., 1985. Activity of 9-[2-hydroxyl-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann. Intern. Med. 103, 368-373.
114. Sherlock, S., 1995. Antiviral therapy for chronic hepatitis C viral infection. J. Hepatol. 23 (Suppl. 2), 3-7.
115. Soul-Lawton, J., Seaber, E., On, N., Wootton, R., Rolan, P., Posner, J., 1995. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob. Agents Chemother. 39, 2759-2764.
116. Soulier, J., Grollet, L., Oksenhendler, E., Cacoub, P., Cazals-Hatem, D., Babinet, P., d'Agay, M.F., Clauvel, J.P., Raphael, M., Degos, L., Sigaux, F., 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86, 1276-1280.
117. Spruance, S.L., 1993. Prophylactic chemotherapy with acyclovir for recurrent herpes simplex labialis. J. Med. Virol. (Suppl. 1), 27-32.
118. Studies of Ocular Complications of AIDS Research Group, 1996. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalvirus retinitis in patients with AIDS. Arch. Ophtalmol. 114, 23-33.
119. Taylor, G., Porter, T., Dillon, S., Trill, J., Ganguly, S., Hart, T., Davis, C., Wyde, P., Tempest, P., Harris, W., 1995. Anti-respiratory syncytial virus monoclonal antibodies show promise in the treatment and prophylaxis of viral disease. Biochem. Soc. Trans. 23, 1063-1067.
120. Tipples, G.A., Ma, M.M., Fischer, K.P., Bain, V.G., Kneteman, N.M., Tyrrell, D.L.J., 1996. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24, 714-717.
121. Van der Meer, J.T.M., Drew, W.L., Bowden, R.A., Galasso, G.J., Griffiths, P.D., Jabs, D.A., Katlama, C., Spector, S.A., Whitley, R.J., 1996. Summary of the International Consensus Symposium in advances in the diagnosis, treatment and prophylaxis of cytomegalovirus infection. Antiviral Res. 32, 119-140.
122. Verdonck, L.F., De Gast, G.C., Dekker, A.W., De Weger, R.A., Schuurman, H.J., Rozenberg-Arska, M., 1989. Treatment of cytomegalovirus pneumonia after bone marrow transplantation with cytomegalovirus immunoglobulins combined with ganciclovir. Bone Marrow Transpl. 4, 187-189.
123. Wei, X., Ghosh, S.K., Taylor, M.E., Johnson, V.A., Emini, E.A., Deutsch, P., Lifson, J.D., Bonhoeffer, S., Nowak, M.A., Hahn, B.H., Saag, M.S., Shaw, G.H., 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122.
124. Weller, S., Blum, M.R., Doucette, M., Burnette, T., Cederberg, D.M., de Miranda, P., Smiley, M.L., 1993. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin. Phramacol. Ther. 54, 595-605.
125. Whimbey, E., Champlin, R.E., Englund, J.E., Mirza, N.Q., Piedra, P.A., Goodrich, J.M., Przepiorua, D., Luna, M., Morice, R.C., Neumann, J.L., Elting, L.S., Bodey, G.P., 1995. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transpl. 16, 393-399.
126. Whitley, R.J., Weiss, M., Gnann, J.W., Tyring, S., Mertz, G.J., Pappas, P.G., Schleupner, C.J., Hayden, F., Wolf, J., Soong, S.J., 1996. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. Ann. Intern. Med. 125, 376-383.
127. Woods, J.M., Bethell, R.C., Coates, J.A., Healy, N., Hiscox, S.A., Pearson, B.A., Ryan, D.M., Ticehurst, J., Tilling, J., Walcott, S.M., Penn, C.R., 1993. 4-guanidino-2,4-dideoxy-2,3-dehydro-N-neuraminic acid is a highly effective inhibitor both of the salidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob. Agents Chemother. 37, 1473-1479.
128. Yerly, S., Kaiser, L., Mermillod, B., Baumberger, C., Hirschel, B., Perrin, L., 1995. Response of HIV RNA to didanosine as a predictive marker of survival. AIDS 9, 159-163.
129. Zhong, W., Wang, H., Herndier, B., Ganem, D., 1996. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc. Natl. Acad. Sci. USA 93, 6641-6646.